Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05927428 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 28, 2024 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3
  2. Enrollment target: 48 to 12v2 Show 6 more changesShow less
    • Primary completion date: Jan 30, 2025 to Aug 30, 2025
    • Start date: Sep 30, 2023 to Jul 31, 2024
    • Primary endpoint revised
    • Study completion date: May 30, 2025 to Nov 30, 2025
    • Interventions: BRM424 Ophthalmic Solution (Drug), Vehicle (Drug) to BRM424 Ophthalmic Solution - Dose1 (Drug), BRM424 Ophthalmic Solution - Dose2 (Drug)
    • Study title expanded, about 1 word
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Trial Details
NCT Number NCT05927428
Lead Sponsor BRIM Biotechnology Inc.
Conditions
(from sponsor)		 Neurotrophic Keratitis
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov